Victory Capital Management Inc. Sells 72,825 Shares of Illumina, Inc. (NASDAQ:ILMN)

Victory Capital Management Inc. reduced its position in Illumina, Inc. (NASDAQ:ILMN - Free Report) by 57.6% during the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 53,550 shares of the life sciences company's stock after selling 72,825 shares during the period. Victory Capital Management Inc.'s holdings in Illumina were worth $7,156,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Bleakley Financial Group LLC purchased a new position in Illumina during the 4th quarter valued at about $751,000. Zacks Investment Management purchased a new position in Illumina during the 3rd quarter valued at about $2,924,000. Van ECK Associates Corp grew its holdings in Illumina by 17.5% during the 4th quarter. Van ECK Associates Corp now owns 152,265 shares of the life sciences company's stock valued at $20,347,000 after buying an additional 22,718 shares in the last quarter. Strategic Financial Concepts LLC purchased a new position in Illumina during the 4th quarter valued at about $1,464,000. Finally, Allworth Financial LP grew its holdings in Illumina by 720.7% during the 4th quarter. Allworth Financial LP now owns 7,132 shares of the life sciences company's stock valued at $1,001,000 after buying an additional 6,263 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors.

Illumina Trading Down 0.6 %

ILMN stock traded down $0.52 during midday trading on Tuesday, hitting $85.16. The company had a trading volume of 1,452,988 shares, compared to its average volume of 2,091,651. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. Illumina, Inc. has a 52 week low of $80.18 and a 52 week high of $156.66. The stock's 50 day moving average price is $112.46 and its 200 day moving average price is $129.53. The stock has a market cap of $13.49 billion, a price-to-earnings ratio of -11.09, a PEG ratio of 1.60 and a beta of 1.17.

Remove Ads

Illumina (NASDAQ:ILMN - Get Free Report) last announced its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 13.37%. As a group, equities research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current fiscal year.

Analysts Set New Price Targets

ILMN has been the subject of a number of recent analyst reports. Guggenheim reduced their target price on Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a report on Friday, February 7th. Robert W. Baird cut their price objective on Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a report on Wednesday, March 5th. Hsbc Global Res lowered Illumina from a "strong-buy" rating to a "hold" rating in a report on Friday, February 28th. Barclays reissued an "underweight" rating on shares of Illumina in a report on Tuesday, March 11th. Finally, Citigroup cut their price objective on Illumina from $130.00 to $90.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat, Illumina currently has an average rating of "Moderate Buy" and a consensus target price of $140.90.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.